A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT04446091
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous adenocarcinoma(MAC).

Key Dates

Start date
Jul 1, 2020
Status verified
Jun 2020
Primary completion
Jul 1, 2021
Completion
Jul 1, 2022

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Two-drug group
    Camrelizumab:200mg,iv,Q2W; Fruquintinib:5mg,po.qd,Day1\~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1\~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1\~21, repeat every 28 days;
  • Experimental: Three-drug group
    Camrelizumab:200mg,iv,Q3W; Irinotecan:150mg/m2,iv 30\~90min,d1,Q3W Fruquintinib:5mg,po.qd,Day1\~21, repeat every 28 days;or Regorafenib: 80mg,po.qd,Day1\~21, repeat every 28 days;or Apatinib:250mg,po.qd,Day1\~21, repeat every 28 days;

Primary Outcome Measure

ORR：Objective Response Rate [ Time Frame: through study completion, an average of 2 year ]

Central Contacts

Related Studies